transfusion-dependent anemia


Also found in: Dictionary, Thesaurus, Encyclopedia.

transfusion-dependent anemia

Anemia for which the only effective therapy is repeated blood transfusions.

CAUTION!

Iron overload may be a complication of therapy, esp. after the transfusion of over 10 units of blood.
See also: anemia
References in periodicals archive ?
REVLIMID is now approved by the FDA for treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.
REVLIMID is an oral medication for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a missing part of chromosome 5 (known as deletion 5q MDS).
Revlimid is designed to treat patients with transfusion-dependent anemia due to low or intermediate risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.
In 2005, Celgene achieved exceptional results in its commercial, financial, clinical and regulatory performance, underscored by the FDA approval of its lead investigational drug REVLIMID for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.
Food and Drug Administration (FDA) granted approval of REVLIMID (lenalidomide) which is indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.
Celgene is seeking authorization to market REVLIMID as a treatment for transfusion-dependent anemia due to low- or intermediate-1- risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.
3 /PRNewswire-FirstCall/ -- Celgene Corporation announced today that they received notification late Friday from the United States Food and Drug Administration (FDA) that the action date for FDA's priority review of the New Drug Application (NDA) for REVLIMID (lenalidomide), for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities, has been extended to January 7, 2006.
ODAC evaluated the REVLIMID NDA for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

Full browser ?